TerrAscend Corp.

TSX:TSND.TO

Drug Manufacturers - Specialty & Generic

Healthcare
$0.52 -1.61%

-$0.02 today

Market cap
$193.65M
Beta
2.04
P/E (TTM)
-2.5
EPS (TTM)
-$0.26
52W Low $0.33High $2.00

Volume 0.26M

Average 0.31M

TSND.TO Financing Cash Flow

Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.

TerrAscend Corp.TSX: TSND.TO

Financing Cash Flow · Q1 FY2026 · quarter ended Mar 2026

Financing cash flow growth accelerates

Q1 FY2026 financing cash flow of $7.02M (cash outflow) rose 200.4% year over year, ahead of the -96.6% change in trailing-twelve-month financing cash flow. Sequentially, it rose 18.4% from the prior quarter. Over 3 fiscal years it compounded at +4.6% a year.

Context

  • Financing cash flow amounted to 1.6% of revenue in FY2025, down 6.5 pp from a year earlier.
  • Financing cash flow increased in 1 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +200.4% holds above the trailing-twelve-month pace of -96.6%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$7.02M+18.4% QoQ
Last fiscal yearDec 2025
$4.26M+117.2% YoY
LTMMar 2026
-$601.11K-96.6% YoY
Financing Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+200.4%——
1 year+117.2%——
3-year CAGR+4.6%——
5-year CAGR——
10-year CAGR——

Financing Cash Flow history

USD · from the cash flow

Latest · FY2025
4.26M USD
Year-over-year change
+117.2%
4-year CAGR
-60.9%

Financing Cash Flow vs competitors

How TSND.TO compares with its peers on the latest reported figures

  • Peers report in different currencies, so financing cash flow is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -96.6% is the 8th highest of 10, against a peer median of -1.0%.
  • Financing cash flow amounts to 0.2% of revenue for TSND.TO, versus a peer median of 32.0%.
TSND.TO Competitors
Financing Cash Flow for TSND.TO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
WEED.TOCanopy Growth CorporationLTM Mar 2026CA$399.12M CAD+168.5%—128.4%
EPRX.TOEupraxia Pharmaceuticals Inc.LTM Mar 2026$122.16M USD+399.3%+78.9%—
DR.TOMedical Facilities CorporationLTM Mar 2026$67.77M USD-43.9%+11.5%22.2%
CPH.TOCipher Pharmaceuticals Inc.LTM Mar 2026$45.54M USD-215.7%+178.1%89.4%
FRX.TOFennec Pharmaceuticals Inc.LTM Mar 2026$25.62M USD+311.3%+6.4%50.1%
HLS.TOHLS Therapeutics Inc.LTM Mar 2026$23.36M USD-1.0%+44.1%41.9%
ACB.TOAurora Cannabis Inc.LTM Mar 2026CA$9.76M CAD+1148.2%—3.1%
XLY.TOAuxly Cannabis Group Inc.LTM Mar 2026CA$6.97M CAD-57.6%—4.4%
OGI.TOOrganiGram Holdings Inc.LTM Mar 2026CA$2.03M CAD-101.9%—0.7%
TSND.TOTerrAscend Corp.LTM Mar 2026$601.11K USD-96.6%+4.6%0.2%
Peer median (excluding TSND.TO) —-1.0%+44.1%32.0%

Competitors are the stored peer set for TSND.TO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(21.82M)22.61M(27.63M)(72.67M)(24.49M)
Depreciation & Amortization13.63M23.87M30.64M22.99M17.51M
Deferred Income Tax(1.81M)(46.02M)(18.92M)(8.75M)(532K)
Stock-Based Compensation14.93M12.18M7.71M9.71M5.01M
Change in Working Capital(45.17M)37.81K35.67M28.84M23.24M
Accounts Receivables(4.02M)3.73M(12.5M)(2.95M)1.67M
Inventory(23.19M)881.27K(7M)4.17M6.05M
Accounts Payables3.53M(15.78M)869.2K(5.29M)(4.59M)
Other Working Capital(21.49M)11.2M52.07M32.91M20.11M
Other Non-Cash Items(4.62K)(38.8M)(2.42K)57.84M1.34M
Operating Cash Flow(38.43M)(33.38M)27.47M37.95M22.07M
Capital Expenditures(50.39M)(54.61M)(9.43M)(10.55M)(8.76M)
Acquisitions (Net)(53.55M)19.77M(16.79M)(250K)(8.68M)
Purchases of Investments(62.65M)0000
Sales of Investments00000
Other Investing Activities34.17M7.27M5.44M(2.64M)3.16M
Investing Cash Flow(132.42M)(27.58M)(16.22M)(12.25M)(15.03M)
Debt Repayment(3.67M)54.4K(27.76M)(17.18M)8.36M
Common Stock Issued200.83M23.62M20.82M00
Common Stock Repurchased000(215K)(417.18K)
Dividends Paid00000
Other Financing Activities(14.96M)(19.95M)(5.56M)(7.32M)(3.69M)
Financing Cash Flow182.2M3.72M(12.5M)(24.72M)4.26M
Effect of Forex Changes2.45M(2.9M)(168K)653K(2.11M)
Net Change in Cash20.42M(52.88M)(1.42M)1.64M9.19M
Free Cash Flow(88.82M)(88M)18.04M27.4M13.31M

TerrAscend Corp.

TSX:TSND.TO

Intrinsic Alpha fair value

Locked

Current Price

$0.52

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.